Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04876066
Status:
UNKNOWN
Last Update Posted:
2022-04-29
First Post:
2021-05-03
Brief Title:
Use of Transmucosal Ketamine in Post Stroke Depression
Sponsor:
West Virginia University
Organization:
West Virginia University
Study Overview
Official Title:
Use of Transmucosal Ketamine in Post Stroke Depression
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Studies have shown that ketamine is very effective and has a quick onset in treatment of depression Most of these studies used intravenous ketamine in an inpatient setting and there are no large trials examining its use in Post Stroke Depression PSD There have been only few studies that have used other routes of administration ie oral transmucosal intranasal intramuscular of ketamine which provided symptom relief for depression The purpose of this study is to assess the effectiveness and safety of use of transmucosal ketamine in treatment of PSD We hypothesize that fast acting antidepressant effects can be achieved with tolerable side effects for translation into the general post-stroke population To test our hypothesis the specific aim is to 1 demonstrate that transmucosal administration of ketamine is feasible within the post-stroke depression population and has tolerable side effects Exploratory aims will include assessment if ketamine also produces fast acting antidepressant effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None